azacitidine has been researched along with Lymphoma, Non-Hodgkin in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (20.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alizadeh, AA; Beaven, AW; Brem, EA; Caimi, PF; Cerchietti, L; Dillon, H; Friedberg, JW; Henry, NL; Laubach, C; LeBlanc, M; Li, H; Little, RF; Olin, R; Smith, SM | 1 |
| Jing, H; Li, M; Wang, J; Wang, W; Ying, J | 1 |
| Andritsos, L; Baiocchi, R; Benson, DM; Blum, KA; Byrd, JC; Chan, KK; Chen, P; Devine, SM; Flynn, J; Grever, MR; Jones, J; Liu, Z; Lucas, DM; Marcucci, G; Plass, C; Xie, Z | 1 |
| Chen, EX; Egorin, MJ; Espinoza-Delgado, I; Hirte, HW; Holleran, JL; Hotte, SJ; Laughlin, A; McGill, S; Moretto, P; Oza, AM; Siu, LL; Stathis, A; Stayner, LA; Wang, L; Webster, S; Zhang, WJ | 1 |
| Chim, CS; Chung, LP; Jin, DY; Lam, WW; Li, GK; Liang, R; Loong, F; So, CC; Wong, KY | 1 |
| Alimena, G; Breccia, M; D'Elia, GM; Loglisci, G; Martelli, M; Mauro, FR; Nanni, M; Salaroli, A | 1 |
| Chen, JH; Hu, WX; Luo, SQ; Pei, JH; Xiao, HW; Zhong, Y | 1 |
| Bo, Y; Ghoshal, K; Jacob, ST; Li, Z; Majumder, S | 1 |
| Greenberg, N; Hurtubise, PE; Schumm, DE; Webb, TE | 1 |
| Chi, CW; Ip, MM | 1 |
3 trial(s) available for azacitidine and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas - Aiming to improve therapy, outcomes, and validate a prospectiv
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Frailty; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Prospective Studies; Rituximab | 2022 |
Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Thrombocytopenia; Treatment Outcome | 2010 |
Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; CpG Islands; Decitabine; Disease Progression; DNA Methylation; Epigenesis, Genetic; Female; Humans; Hydroxamic Acids; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Promoter Regions, Genetic; Time Factors; Vorinostat | 2011 |
7 other study(ies) available for azacitidine and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
5-Azacitidine induces demethylation of PTPL1 and inhibits growth in non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Cell Proliferation; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Promoter Regions, Genetic; Protein Tyrosine Phosphatase, Non-Receptor Type 13 | 2015 |
Epigenetic inactivation of the miR-124-1 in haematological malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Blotting, Western; Cell Line, Tumor; Chromatin Immunoprecipitation; Cyclin-Dependent Kinase 6; Epigenesis, Genetic; Female; Hematologic Neoplasms; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin; Male; Methylation; MicroRNAs; Middle Aged; Multiple Myeloma; Reverse Transcriptase Polymerase Chain Reaction; Young Adult | 2011 |
5'-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes | 2011 |
The association between non-Hodgkin lymphoma and methylation of p73.
Topics: Adult; Antimetabolites, Antineoplastic; Azacitidine; Blotting, Western; Decitabine; DNA Methylation; DNA-Binding Proteins; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nuclear Proteins; Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Tumor Protein p73; Tumor Suppressor Proteins; Young Adult | 2011 |
Silencing of metallothionein-I gene in mouse lymphosarcoma cells by methylation.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Base Sequence; CpG Islands; DNA Footprinting; DNA Methylation; DNA, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Silencing; Lymphoma, Non-Hodgkin; Metallothionein; Metals, Heavy; Mice; Molecular Sequence Data; Neoplasm Proteins; Promoter Regions, Genetic; Regulatory Sequences, Nucleic Acid; Thymus Gland; Transcription Factors; Tumor Cells, Cultured | 1999 |
Uridine kinase activities in normal and neoplastic lymphoid cells.
Topics: Animals; Azacitidine; B-Lymphocytes; Carcinoma, Hepatocellular; Cats; Enzyme Induction; Humans; Isoenzymes; Leukemia, Experimental; Leukemia, Lymphoid; Liver Neoplasms; Lymphocyte Activation; Lymphocytes; Lymphoma, Non-Hodgkin; Male; Mast-Cell Sarcoma; Mice; Middle Aged; Neoplasms; Neoplasms, Experimental; Phosphotransferases; Rats; T-Lymphocytes; Uridine Kinase | 1977 |
Combined therapy with 5-azacytidine and hydrocortisone in glucocorticoid-sensitive and -resistant mouse P1798 lymphosarcoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; DNA, Neoplasm; Drug Resistance; Female; Hydrocortisone; Lymphoma, Non-Hodgkin; Male; Mice; Receptors, Glucocorticoid; Tumor Cells, Cultured | 1988 |